Download PDF
Int J Angiol 2017; 26(01): 043-048
DOI: 10.1055/s-0036-1593409
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease

Patrick J. Sweigert
1   Stritch School of Medicine, Loyola University of Chicago, Maywood
,
Vinod K. Bansal
2   Division of Nephrology, Department of Internal Medicine, Loyola University Medical Center, Maywood
,
Debra A. Hoppensteadt
3   Division of Hemostasis and Thrombosis, Department of Pathology, Loyola University Medical Center, Maywood
,
Jennifer L. Saluk
1   Stritch School of Medicine, Loyola University of Chicago, Maywood
,
Daneyal A. Syed
3   Division of Hemostasis and Thrombosis, Department of Pathology, Loyola University Medical Center, Maywood
,
Jawed Fareed
3   Division of Hemostasis and Thrombosis, Department of Pathology, Loyola University Medical Center, Maywood
› Author Affiliations
Further Information

Publication History

Publication Date:
05 October 2016 (online)

    Permissions and Reprints

Abstract

End-stage renal disease (ESRD) presents a complex syndrome in which inflammatory and metabolic processes contribute to disease progression and development of comorbid conditions. Over $1 trillion is spent globally on ESRD care.

Plasma samples collected from 83 ESRD patients prior to hemodialysis were profiled for metabolic and inflammatory biomarker concentrations. Concentrations were compared between groups with and without history of stroke, acute coronary syndrome (ACS), congestive heart failure (CHF), and coronary artery disease (CAD).

The 25 patients (30.1%) with history of stroke demonstrated decreased plasma interferon-γ levels (p = 0.042) and elevated plasma resistin, interleukin (IL)-1α, and leptin levels (p = 0.008, 0.021, 0.026, respectively) when compared with ESRD patients without history of stroke. The 14 patients (16.9%) with history of ACS demonstrated elevated plasma IL-6 levels (p = 0.040) when compared with ESRD patients without history of ACS. The 30 patients (36.1%) with history of CHF demonstrated decreased plasma leptin levels (p = 0.031) and elevated plasma IL-1β levels (p = 0.042) when compared with ESRD patients without history of CHF. Finally, the 39 patients (47.0%) with history of CAD demonstrated elevated plasma IL-1α levels (p = 0.049) when compared with ESRD patients without history of CAD.

Plasma biomarker concentration disturbances were observed in ESRD patients with history of stroke, ACS, CHF, and CAD when compared with ESRD patients without such history. Proinflammatory biomarker elevations were seen in stroke, ACS, CHF and CAD, while adipocytokine aberrations were observed in both stroke and CHF. These studies demonstrate that biomarker profiling of vascular comorbidities in ESRD may provide useful diagnostic and prognostic information in the management of ESRD patients.

Keywords

acute coronary syndrome - cardiovascular disease - hemodialysis - myocardial infarction - renal failure - stroke - tumor necrosis factor-α
 

  • References

  • 1 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351 (13) 1296-1305
    CrossrefPubMedGoogle Scholar
  • 2 Sarnak MJ, Levey AS, Schoolwerth AC , et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42 (5) 1050-1065
    CrossrefPubMedGoogle Scholar
  • 3 Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45 (2) 275-280
    CrossrefPubMedGoogle Scholar
  • 4 Lamprea-Montealegre JA, McClelland RL, Astor BC , et al. Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 2013; 33 (3) 652-658
    CrossrefPubMedGoogle Scholar
  • 5 Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013; 29 (7, Suppl): S71-S78
    CrossrefPubMedGoogle Scholar
  • 6 Slee AD. Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab (Lond) 2012; 9 (1) 36
    CrossrefPubMedGoogle Scholar
  • 7 Mills KT, Hamm LL, Alper AB , et al. Circulating adipocytokines and chronic kidney disease. PLoS One 2013; 8 (10) e76902
    CrossrefPubMedGoogle Scholar
  • 8 Alix PM, Guebre-Egziabher F, Soulage CO. Leptin as an uremic toxin: deleterious role of leptin in chronic kidney disease. Biochimie 2014; 105: 12-21
    CrossrefPubMedGoogle Scholar
  • 9 Cumin F, Baum HP, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord 1996; 20 (12) 1120-1126
    PubMedGoogle Scholar
  • 10 Bełtowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006; 24 (5) 789-801
    CrossrefPubMedGoogle Scholar
  • 11 Fontana A, Spadaro S, Copetti M , et al. Association between resistin levels and all-cause and cardiovascular mortality: a new study and a systematic review and meta-analysis. PLoS One 2015; 10 (3) e0120419
    CrossrefPubMedGoogle Scholar
  • 12 Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1 (2) e45
    CrossrefPubMedGoogle Scholar
  • 13 Nehus E, Furth S, Warady B, Mitsnefes M. Correlates of resistin in children with chronic kidney disease: the chronic kidney disease in children cohort. J Pediatr 2012; 161 (2) 276-280
    CrossrefPubMedGoogle Scholar
  • 14 Axelsson J, Bergsten A, Qureshi AR , et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69 (3) 596-604
    CrossrefPubMedGoogle Scholar
  • 15 Alberti KG, Eckel RH, Grundy SM , et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120 (16) 1640-1645
    CrossrefPubMedGoogle Scholar
  • 16 Saluk J, Bansal V, Hoppensteadt D, Syed D, Abro S, Fareed J. Prevalence of metabolic syndrome in patients with end stage renal disease and relevance of biomarkers. Int Angiol 2016; 35 (1) 47-56
    PubMedGoogle Scholar
  • 17 Wouters OJ, O'Donoghue DJ, Ritchie J, Kanavos PG, Narva AS. Early chronic kidney disease: diagnosis, management and models of care. Nat Rev Nephrol 2015; 11 (8) 491-502
    CrossrefPubMedGoogle Scholar
  • 18 Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and mechanisms of uremia-related cardiovascular disease. Circulation 2016; 133 (5) 518-536
    CrossrefPubMedGoogle Scholar
  • 19 Bian X, Liu N, Bai Y , et al. Association of leptin with mortality in patients on maintenance hemodialysis: a prospective study. Iran J Kidney Dis 2014; 8 (4) 314-320
    PubMedGoogle Scholar
  • 20 Cohen SD, Phillips TM, Khetpal P, Kimmel PL. Cytokine patterns and survival in haemodialysis patients. Nephrol Dial Transplant 2010; 25 (4) 1239-1243
    CrossrefPubMedGoogle Scholar
  • 21 Ghanavatian S, Diep LM, Bárány P , et al. Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. Angiology 2014; 65 (5) 443-449
    CrossrefPubMedGoogle Scholar